Lipid‐lowering properties of TAK‐475, a squalene synthase inhibitor, in vivo and in vitro
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid‐lowering properties of 1‐[[(3 R,5 S)‐1‐(3‐acetoxy‐2,2‐dimethylpropyl)‐7‐chloro‐5‐(2,3‐dimethoxyphenyl)‐2‐oxo‐1,2,3,5‐tetrahydro‐4,1‐benzoxazepin‐3‐yl]acetyl]piperidine‐4‐acetic acid (TAK‐475), a novel squalene synthase inhibitor. TAK‐475 inhibited hepatic cholesterol biosynthesis in rats (ED 50, 2.9 mg kg−1) and showed lipid‐lowering effects in beagle dogs, marmosets, cynomolgus monkeys and Wistar fatty rats. In marmosets, TAK‐475 (30, 100 mg kg−1, p.o., for 4 days) lowered both plasma non‐high‐density lipoprotein (HDL) cholesterol and triglyceride, but did not affect plasma HDL cholesterol. On the other hand, atorvastatin (10, 30 mg kg−1, p.o., for 4 days) lowered the levels of all these lipids. A correlation between decrease in triglyceride and increase in HDL cholesterol was observed, and TAK‐475 increased HDL cholesterol with a smaller decrease in triglyceride than did atorvastatin. TAK‐475 (60 mg kg−1, p.o., for 15 days) suppressed the rate of triglyceride secretion from the liver in hypertriglyceridemic Wistar fatty rats, which show an enhanced triglyceride secretion rate from the liver compared with their lean littermates. In HepG2 cells, TAK‐475 and its pharmacologically active metabolite, T‐91485, increased the binding of 125 I‐low‐density lipoprotein (LDL) to LDL receptors. 6 These results suggest that TAK‐475 has clear hypolipidemic effects in animals via inhibition of hepatic triglyceride secretion and upregulation of LDL receptors, and that TAK‐475 might increase HDL cholesterol by decreasing triglyceride. Thus, TAK‐475 is expected to be useful for the treatment of dyslipidemia. British Journal of Pharmacology (2003) 139, 911–918. doi:10.1038/sj.bjp.0705332
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma triglyceride and coronary heart disease
Austin, M. A. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.2 · Cited by 697 · cited 3×
“Many epidemiological studies, including the Framingham Heart Study, have established an association between dyslipidemia and increased risk of coronary heart disease (CHD) (Gordon et al., 1981; Anderson et al., 1987).”
BackgroundInfluential
Cited by
A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E. (2008) · Science · doi:10.1126/science.1153018 · Cited by 490
PCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
Fukuma, Y., Matsui, H., Koike, H., Sekine, Y., Shechter, I., Ohtake, N., Nakata, S., Ito, K., & Suzuki, K. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.14 · Cited by 39
Metadata
- Authors
- Nishimoto, T., Amano, Y., Tozawa, R., Ishikawa, E., Imura, Y., Yukimasa, H., & Sugiyama, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-07
- Volume
- 139
- Issue
- 5
- Pages
- 911-918
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2036941642
- Cited by
- 71
- References
- 1
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.